BURROUGHS WELLCOME ANTIDEPRESSANT WELLBUTRIN APPROVAL AT YEAR-END IS SOURCE OF HOLIDAY CHEER; PRODUCT LAUNCH IN SPRING WILL GIVE FIRM NEW PRODUCT CLASS FOR 1986
Burroughs Wellcome's Wellbutrin (buproprion) for second line treatment of depression will be launched in "early spring," according to the company. FDA approved the drug Dec. 30, four years after Burroughs Wellcome filed an NDA in December 1981 and one year after FDA determined the drug was approvable. Approved labeling states: "Wellbutrin is indicated for the treatment of depression in patients who fail to respond adequately to, or who cannot tolerate, alternative antidepressant treatments. Wellbutrin is not recommended as an antidepressant of first choice for most patients because its use at doses approximately one-and-one-third times greater than the usual required daily dose (450 mg) is associated with a high risk of seizure." The agency classified Wellbutrin as a 1B drug, signifying a new chemical entity with modest therapeutic gain over other marketed drugs. The drug gives Burroughs-Wellcome an entry into the antidepressant market. Labeling includes a bold faced warning against use in patients with seizures. The physician insert also notes that Wellbutrin should not be used with monoamine oxidase inhibitors or in patients who have shown an allergic reaction to the drug. With regard to length of therapy, the labeling states: "While it is generally recommended that a course of antidepressant drug treatment should continue for several months and many patients have been treated with Wellbutrin in long-term clinical trials of up to two years duration, there has been no systematic placebo controlled evaluation of the efficacy of Wellbutrin for a period beyond three to four weeks." FDA's Psychopharmacologic Drugs Advisory Cmte. recommended approval of Wellbutrin in June 1982. At that time, cmte. reviewer Donald Robinson, MD, Marshall University, said the data supported short-term efficacy but effectiveness was not shown for long-term use.
You may also be interested in...
Newly released Medicare Part D data sheds light on the sales hit that branded pharmaceutical manufacturers will face when the coverage gap discount program gets under way in 2011
FDA appears headed for a showdown with clinicians and the pharmaceutical industry over the proposed new clinical trial endpoints for acute bacterial skin and skin structure infections, the guidance's approach for justifying a non-inferiority margin and proposed changes in the types of patients that should be enrolled in trials
Specialty drug maker Shire has quietly begun scouting deals with a brand-new $50 million venture fund, the latest of several in-house investment arms to launch with their parent company's pipelines, not profits, as the measure of their worth